Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-01-21
2010-02-02
Landsman, Robert (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600
Reexamination Certificate
active
07655751
ABSTRACT:
The object of the invention is to provide an EGFR-derived peptide useful for EGFR-based immunotherapy.The invention provides an EGFR-derived peptide capable of inducing both cellular and humoral immune responses and mutant peptide thereof and a polypeptide comprising said peptide, a nucleic acid molecule encoding the same, and a pharmaceutical composition comprising the same.
REFERENCES:
patent: 00/18895 (2000-04-01), None
patent: 2004/067029 (2004-08-01), None
Y. Lu et al., “Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor”, The Journal of Immunology, vol. 170, No. 6, pp. 3162-3170, Mar. 15, 2003.
H. Takedatsu et al., “Expression of Epithelial Cancer-Related Antigens in Hematologic Malignancies Applicable for Peptide-Based Immunotherapy”, Journal of Immunotherapy, vol. 27, pp. 289-297, 1997.
T. Mine et al ., “Immunological Evaluation of CTL Precursor-Oriented Vaccines for Advanced Lung Cancer Patients”, Cancer Science, vol. 94, No. 6, pp. 548-556, Jun. 6, 2003.
G. Gonzalez et al., “Epidermal Growth Factor-Based Cancer Vaccine for Non-Small-Cell Lung Cancer Therapy”, Annals of Oncology, vol. 14, No. 3, pp. 461-466, Mar. 2003.
R. S.Herbst et al., “Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer”, Clinical Cancer Research, vol. 9, pp. 5813-5824, Dec. 1, 2003.
H. Shomura et al., “Identification of Epidermal Growth Factor Receptor-Derived Peptides Immunogenic for HLA-A2+Cancer Patients”, British Journal of Cancer, vol. 90, No. 8, pp. 1563-1571, Apr. 19, 2004.
T. Yamamoto et al., “Similarity of protein encoded by the humanc-erb-B-2 gene to epidermal growth factor receptor”, Nature, vol. 319, pp. 230-234, Jan. 16, 1986.
L. Coussens et al., “Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location withneuoncogene”, Science, vol. 230, pp. 1132-1139, Dec. 1985.
D. S. Salomon et al., “Epidermal growth factor-related peptides and their receptors in human malignancies”, Critical Reviews in Oncology/Hematology, vol. 19, pp. 183-232, 1995.
V. A. Miller et al., “Pilot trail of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer”, Journal of Clinical Onocology, vol. 21, No. 11, pp. 2094-2100, Jun. 1, 2003.
M. Fukuoka et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer”, Journal of Clinical Oncology, vol. 21, No. 12, pp. 2237-2246, Jun. 15, 2003.
G. E. Peoples et al., “Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2
eu-derived peptide”, Proc. Natl. Acad. Sci., vol. 92, pp. 432-436, Jan. 1995.
B. Fisk et al., “Identification of an immunodominant peptide of HER-2
eu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines”, J. Exp. Med., vol. 181, pp. 2109-2117, Jun. 1995.
I. Kawashima et al., “Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2
euby primary in vitro immunization with peptide-pulsed dendritic cells”, Cancer Research, vol. 59, pp. 431-435, Jan. 15, 1999.
T. Okugawa et al., “A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals”, Eur. J. Immunol., vol. 30, pp. 3338-3346, 2000.
M. Noguchi et al., “Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination”, The Prostate, vol. 57, pp. 80-92, 2003.
Y. Sato et al., “Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide”, Cancer Science, vol. 94, No. 9, pp. 802-808, Sep. 2003.
T. Mine et al., “Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients”, Cancer Sci., vol. 94, No. 6, pp. 548-556, Jun. 2003.
M. H. Parkar et al., “Expression of growth-factor receptors in normal and regenerating human periodontal cells”, Archives of Oral Biology, vol. 46, pp. 275-284, 2001.
M. L. Disis et al., “High-titer HER-2
euprotein-specific antibody can be detected in patients with early-stage breast cancer”, Journal of Clinical Oncology, vol. 15, No. 11, pp. 3363-3367, Nov. 1997.
E. Jager et al., “Induction of primary NY-ESO-1 immunity: CD8 + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers”, Proc. Natl. Acad. Sci., vol. 97, No. 22, pp. 12198-12203, Oct. 24, 2000.
S. Ohkouchi et al.,“Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals”, Tissue Antigens, vol. 59, pp. 259-272, 2002.
N. Kawamoto et al., “IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients”, Tissue Antigens, vol. 61, pp. 352-361, 2003.
T. Imanishi et al., “Allele and haplotype frequencies for HLA and complement loci in various ethnic groups”, In: Proceedings of the Eleventh International Histocompatibility Workshop and Conference, pp. 1065-1220, Oxford University Press, Oxford, United Kingdom, 1992.
J. Dancey et al., “Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment”, Nature Rev. Drug Discovery , vol. 2, pp. 296-313, Apr. 2003.
Y. Yarden et al., “Untangling the ErbB signalling network”, Nature Rev. Molecular Cell Biology, vol. 2, pp. 127-137, Feb. 2001.
J. Baselga et al., “Why the epidermal growth factor receptor? The rationale for cancer therapy”, The Oncologist, vol. 7, Suppl. 4, pp. 2-8, 2002.
R. S. Herbst et al., “Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a Phase I trial”, Journal of Clinical Oncology, vol. 20, No. 18, pp. 3815-3825, Sep. 15, 2002.
Ch. Dittrich et al., “Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration”, European Journal of Cancer, vol. 38, pp. 1072-1080, 2002.
J. Mendelsohn et al., “Status of epidermal growth factor receptor antagonist in the biology and treatment of cancer”, Journal of Clinical Oncology, vol. 21, No. 14, pp. 2787-2799, Jul. 15, 2003.
C. Meyer zum Buschenfelde et al., “The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells”, The Journal of Immunology, vol. 167, pp. 1712-1719, 2001.
D. K. Moscatello et al., “A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors”, Cancer Research, vol. 57, pp. 1419-1424, Apr. 15, 1997.
A. Ullrich et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells”, Nature, vol. 309, pp. 418-425, May 31, 1984.
A. T. Baron et al., “Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain”, Hybridoma, vol. 16, No. 3, pp. 259-271, 1997.
H. Shomura et al., “Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+non-small cell lung cancer patients”, European Journal of Cancer, vol. 40, pp. 1776-1786, 2004.
Canadian Office Action issued Apr. 3, 2009 in connection wi
Itoh Kyogo
Shichijo Shigeki
Green Peptide Co., Ltd.
Landsman Robert
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Epidermal growth factor receptor-derived peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epidermal growth factor receptor-derived peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epidermal growth factor receptor-derived peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201378